Subscribe Us

header ads

Recents

header ads

Drug Discovery Services Market Size to Attain USD 33.2 Billion By 2030

 The drug discovery services market size is poised to grow by $ 33.2  billion by 2030 from $ 14.11 Billion in 2022, exhibiting a CAGR of 11.3% during the forecast period 2022 to 2030.

Drug Discovery Services Market Size 2022 to 2030

 

The main objective of this report is to define, describe, and forecast the global market by types, application, manufacturers, and regions. The report provides detailed information about the major factors (drivers, restraints, opportunities, and industry-specific challenges) influencing the growth of the market. The report aims to strategically analyze the micro markets with respect to individual growth trends, prospects, and contributions to the global market. The report also attempts to forecast the market size of the 5 main regions: North America, Europe, Asia Pacific (APAC), Middle East and Africa (MEA), and Latin America. It strategically profiles the key market players and comprehensively analyzes their core competencies. It also tracks and analyzes competitive developments, such as joint ventures, mergers and acquisitions, new developments, and Research and Development (R&D) activities, in market.

Get a Sample: https://www.precedenceresearch.com/sample/1532 

COVID-19 Impact

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the electric vehicle fuel cell market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Major companies operating in this are

  • Abbott Laboratories Inc.
  • Advinus Therapeutics
  • Agilent Technologies Ubiquigent
  • Albany Molecular Research Inc.
  • AstraZeneca PLC
  • Aurigene
  • Bayer AG
  • Charles River Laboratories International
  • ChemBridge Corporation
  • Covance

Market Segmentation

By Process

  • Target Selection
  • Target Validation
  • Hit to Lead Identification
  • Lead Optimization
  • Candidate Validation

By Drug Type

  • Small Molecules
  • Biologics

By Type

  • DMPK
  • Biology Services
  • Medicinal Chemistry

By Therapeutic Area

  • Oncology
  • Cardiovascular Diseases
  • Diabetes
  • Neurology
  • Respiratory Diseases
  • Others

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Major highlights of Report:

  • Figures related to sales volume, market remuneration, and segmental shares
  • Featuring market dynamics
  • Growth prospects and expansion graph
  • PROCON study of direct & indirect sales channels
  • Profiles of prominent traders, dealer, and distributors in the industry

Geographical landscape: North America, Europe, Asia-Pacific, South America, Middle East and Africa

  • Industry forecasts based on region and at country level
  • Data about sales volume recorded, industry share held, and profit margins amassed
  • Overall remuneration and estimated growth rate for each regional market

Major Key Points Covered in Report:

Executive Summary: It includes key trends of the electric vehicle fuel cell market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the electric vehicle fuel cell market based on production and revenue.

Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.

Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Electric vehicle fuel cell market.

Market Segments: This part of the report discusses product, application and other segments of the electric vehicle fuel cell market based on market share, CAGR, market size, and various other factors.

Research Methodology: This section discusses the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Drug Discovery Services Market 

5.1. COVID-19 Landscape: Drug Discovery Services Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Drug Discovery Services Market, By Process

8.1. Drug Discovery Services Market, by Process Type, 2021-2030

8.1.1. Target Selection

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Target Validation

8.1.2.1. Market Revenue and Forecast (2019-2030)

8.1.3. Hit to Lead Identification

8.1.3.1. Market Revenue and Forecast (2019-2030)

8.1.4. Lead Optimization

8.1.4.1. Market Revenue and Forecast (2019-2030)

8.1.5. Candidate Validation

8.1.5.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Drug Discovery Services Market, By Drug Type

9.1. Drug Discovery Services Market, by Drug Type, 2021-2030

9.1.1. Small Molecules

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Biologics

9.1.2.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Drug Discovery Services Market, By Type

10.1. Drug Discovery Services Market, by Type, 2021-2030

10.1.1. DMPK

10.1.1.1. Market Revenue and Forecast (2019-2030)

10.1.2. Biology Services

10.1.2.1. Market Revenue and Forecast (2019-2030)

10.1.3. Medicinal Chemistry

10.1.3.1. Market Revenue and Forecast (2019-2030)

Chapter 11. Global Drug Discovery Services Market, By Therapeutic Area

11.1. Drug Discovery Services Market, by Therapeutic Area Type, 2021-2030

11.1.1. Oncology

11.1.1.1. Market Revenue and Forecast (2019-2030)

11.1.2. Cardiovascular Diseases

11.1.2.1. Market Revenue and Forecast (2019-2030)

11.1.3. Diabetes

11.1.3.1. Market Revenue and Forecast (2019-2030)

11.1.4. Neurology

11.1.4.1. Market Revenue and Forecast (2019-2030)

11.1.5. Respiratory Diseases

11.1.5.1. Market Revenue and Forecast (2019-2030)

11.1.6. Others

11.1.6.1. Market Revenue and Forecast (2019-2030)

Chapter 12. Global Drug Discovery Services Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Process (2019-2030)

12.1.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.1.3. Market Revenue and Forecast, by Type (2019-2030)

12.1.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Process (2019-2030)

12.1.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.1.5.3. Market Revenue and Forecast, by Type (2019-2030)

12.1.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Process (2019-2030)

12.1.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.1.6.3. Market Revenue and Forecast, by Type (2019-2030)

12.1.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Process (2019-2030)

12.2.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.2.3. Market Revenue and Forecast, by Type (2019-2030)

12.2.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Process (2019-2030)

12.2.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.2.5.3. Market Revenue and Forecast, by Type (2019-2030)

12.2.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Process (2019-2030)

12.2.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.2.6.3. Market Revenue and Forecast, by Type (2019-2030)

12.2.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Process (2019-2030)

12.2.7.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.2.7.3. Market Revenue and Forecast, by Type (2019-2030)

12.2.7.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Process (2019-2030)

12.2.8.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.2.8.3. Market Revenue and Forecast, by Type (2019-2030)

12.2.8.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Process (2019-2030)

12.3.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.3.3. Market Revenue and Forecast, by Type (2019-2030)

12.3.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Process (2019-2030)

12.3.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.3.5.3. Market Revenue and Forecast, by Type (2019-2030)

12.3.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Process (2019-2030)

12.3.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.3.6.3. Market Revenue and Forecast, by Type (2019-2030)

12.3.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Process (2019-2030)

12.3.7.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.3.7.3. Market Revenue and Forecast, by Type (2019-2030)

12.3.7.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Process (2019-2030)

12.3.8.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.3.8.3. Market Revenue and Forecast, by Type (2019-2030)

12.3.8.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Process (2019-2030)

12.4.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.4.3. Market Revenue and Forecast, by Type (2019-2030)

12.4.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Process (2019-2030)

12.4.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.4.5.3. Market Revenue and Forecast, by Type (2019-2030)

12.4.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Process (2019-2030)

12.4.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.4.6.3. Market Revenue and Forecast, by Type (2019-2030)

12.4.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Process (2019-2030)

12.4.7.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.4.7.3. Market Revenue and Forecast, by Type (2019-2030)

12.4.7.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Process (2019-2030)

12.4.8.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.4.8.3. Market Revenue and Forecast, by Type (2019-2030)

12.4.8.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Process (2019-2030)

12.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.5.3. Market Revenue and Forecast, by Type (2019-2030)

12.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Process (2019-2030)

12.5.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.5.5.3. Market Revenue and Forecast, by Type (2019-2030)

12.5.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Process (2019-2030)

12.5.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)

12.5.6.3. Market Revenue and Forecast, by Type (2019-2030)

12.5.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2019-2030)

Chapter 13. Company Profiles

13.1. Abbott Laboratories Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Advinus Therapeutics

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Agilent Technologies Ubiquigent

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Albany Molecular Research Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. AstraZeneca PLC

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Aurigene

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Bayer AG

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Charles River Laboratories International

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. ChemBridge Corporation

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Covance

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com

Post a Comment

0 Comments